Active-Controlled Trial of the Safety and Tolerability of a MP03-33 in Patients With Chronic Allergic or Nonallergic Rhinitis.
Phase of Trial: Phase III
Latest Information Update: 26 Feb 2017
At a glance
- Drugs Azelastine (Primary)
- Indications Perennial allergic rhinitis; Vasomotor rhinitis
- Focus Adverse reactions
- Sponsors Meda Pharmaceuticals
- 23 Nov 2008 New trial record.